Pharmacist Pleads Guilty in Hepatitis C Drug Fraud Case

A former Clinical Pharmacy Manager at a Walgreens specialty pharmacy pleaded guilty to health care fraud crimes committed between October 2014 and April 2016.
Amber Reilly, a Tennessee pharmacist, admitted to falsifying prior authorizations, medical lab reports, and drug test results for at least 51 hepatitis C patients who were prescribed expensive hepatitis C drugs Sovaldi, Harvoni, Viekira Pak, and Daklinza.
Although the patients’ authentic lab reports and drug tests showed that they failed to meet TennCare eligibility requirements, Reilly replaced the disqualifying information with qualifying information. TennCare does not pay for hepatitis C prescriptions for patients who are shown to abuse illicit substances or who have limited or no liver scarring. Reilly fabricated the patients’ test results in order to eliminate disqualifying information, and then submitted the fraudulent records to TennCare.
Reilly also admitted to falsifying allergies on prior authorization forms for some patients so that they could receive Harvoni, which is the most expensive hepatitis C drug.
As a result, TennCare paid at least $4,400,000 to purchase hepatitis C prescriptions for these 51 patients. Reilly is set for sentencing on January 30, 2017. If convicted, she faces a potential sentence of up to 10 years in prison, a $250,000 fine, and supervised release of up to 3 years.  

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.
The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.